leisure time -WSS

leisure time

author：explore 2025-09-29 19:06:25 - browse：594

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： PBM reform efforts get punted in Congress

Wikipedia

focus

WSS

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

UnitedHealth quietly bought dozens of outpatient centers

NEJM study link tiny plastics in blood vessels to heart problems

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

A new nitrogen execution bill also undermines medical licensing

The problem with charging patients to message their doctors

leisure time

leisure time

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

In Memoriam: Notable people who died in 2023

With competition flaring, obesity drug hits goal in liver disease study

After affirmative action ruling, medical educators look to 'holistic review'

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Sports medicine is finally prioritizing gender equality

NIH study of ME/CFS points to clear biological hallmarks

Duchenne breakthrough therapy leaves behind pioneering families

What it’s like to watch children die of measles

hotspot

With competition flaring, obesity drug hits goal in liver disease study

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

PBM reform efforts get punted in Congress

Novo Nordisk obesity pill bests Wegovy in early trial

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Wikipedia

focus

focus

entertainment